Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Company Deals Digital

Merck & Co. Announces $1 Billion Strategic Partnership with Google Cloud to Deploy Enterprise-Wide Agentic AI Platform

Fineline Cube Apr 23, 2026
Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Fineline Cube Apr 22, 2026
Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Fineline Cube Apr 22, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Fineline Cube Apr 23, 2026
Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Fineline Cube Apr 23, 2026
Company

Taizhou-Wuxi-Lianyungang Biomedicine Hub Launched at China Medical Expo

Fineline Cube Nov 28, 2022

The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine...

Company Deals

Huadong Medicine Partners with Dongyang Med for Equity Collaboration

Fineline Cube Nov 28, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced an equity collaboration deal with Zhejiang...

Company Drug

Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes

Fineline Cube Nov 28, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products...

Drug

Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia

Fineline Cube Nov 25, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary,...

Company Medical Device

Peijia Medical Announces First Patient Implant in MonarQ TTVR System Clinical Study

Fineline Cube Nov 25, 2022

China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global...

Company Deals

Zhejiang Dian Diagnostics Partners with Chengdu Eastern New Area for IVD Hub

Fineline Cube Nov 25, 2022

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu...

Company Deals

Anyeep Raises RMB 100 Million in Series A Financing for Mass Spectrometry Development

Fineline Cube Nov 25, 2022

Anyeep, a Suzhou-based developer of mass spectrometers, has reportedly raised close to RMB 100 million...

Company Deals

Shanghai Henlius Biotech to Provide R&D Services for COVID-19 Therapy Azvudine

Fineline Cube Nov 25, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has entered into an agreement to provide clinical study...

Company Drug

China Resources Double-Crane Gains Approval for Definity in China

Fineline Cube Nov 25, 2022

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving market approval from the...

Company Deals

XtalPi Partners with CK Life Sciences to Develop AI Cancer Vaccine Platform

Fineline Cube Nov 25, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with China-based CK Life...

Company Drug

Bliss Bio’s BB-1709 Accepted for Review by China’s CDE

Fineline Cube Nov 25, 2022

Hangzhou-based oncology-focused clinical stage biotech Bliss Bio has announced that its clinical filing for the...

Company Deals

Xiling Lab Raises RMB 100 Million for ADC Development and IND Filing

Fineline Cube Nov 25, 2022

Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close...

Company Deals

PrimeLink Bio Raises Funds for ADC Development and R&D Expansion

Fineline Cube Nov 25, 2022

Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a...

Company Medical Device

AnchorDx’s UriFind Receives Breakthrough Therapy Designation for Urothelial Carcinoma

Fineline Cube Nov 24, 2022

China-based Guangzhou AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing, has obtained a...

Company Deals

Visen Pharmaceuticals Files for Hong Kong IPO with Focus on Growth Hormone

Fineline Cube Nov 24, 2022

Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...

Company Drug

Junshi Biosciences Files for UK Approval of PD-1 Inhibitor Tuoyi

Fineline Cube Nov 24, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has filed for market...

Company

CSPC Pharmaceutical Reports Q3 2022 Financials with 13.8% Revenue Growth

Fineline Cube Nov 24, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has released its Q3 2022 financial results, reporting...

Company Policy / Regulatory

Tianjin Tianyao Fined for Anti-Monopoly Violations in Carmustine Sales

Fineline Cube Nov 24, 2022

China-based Tianjin Tianyao Pharmaceutical Co., Ltd (SHA: 600488) has been fined RMB 27.72 million (USD...

Policy / Regulatory

China Releases Third Batch of VAT Discounts for Anti-Tumor and Rare Disease Drugs

Fineline Cube Nov 24, 2022

The Ministry of Finance, General Administration of Customs, State Taxation Administration, and National Medical Products...

Company Deals

OrbusNeich Files for IPO on Hong Kong Stock Exchange

Fineline Cube Nov 24, 2022

Vascular intervention specialist OrbusNeich Medical Group Limited, a Wholly Owned Foreign Enterprise (WOFE) based in...

Posts pagination

1 … 585 586 587 … 656

Recent updates

  • Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds
  • Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026
  • Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month
  • Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals
  • Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds

Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Company

Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.